Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 11, 2026
Why Is Life360 (LIF) Stock Down -26% Today?

Why Is Life360 (LIF) Stock Down -26% Today?

Key Takeaways

  • Life360 shares plunged approximately 26% on Tuesday, erasing roughly $1.7 billion in market value, following the company's second-quarter earnings report released after Monday's close.
  • Primary catalyst: Despite beating on Q2 revenue ($159 million vs. $156.7 million consensus) and adjusted EBITDA, investors recoiled at decelerating monthly active user (MAU) growth, unchanged full-year guidance, and softer near-term margin projections.
  • Secondary drivers: GAAP net income fell 28% year-over-year to $5.1 million, EPS missed consensus ($0.06 vs. $0.08 expected), and operating expenses surged 43%, outpacing the 38% revenue growth rate.
  • MAU growth concerns: MAU growth slowed to 16% year-over-year — a second consecutive deceleration — casting doubt on management's ability to achieve its full-year 20% growth target without a sharp second-half reacceleration.
  • Broader context: The selloff fits a pattern for high-multiple growth stocks where even modest deceleration in key forward-looking metrics triggers severe multiple compression.
  • What to watch: Traders are now focused on whether back-to-school seasonality, the Pet GPS relaunch, and advertising platform commercialization can reignite MAU momentum in the third quarter.

Opening Summary

Shares of LIF, the family-focused safety and location-sharing platform operator Life360 Inc., cratered roughly 26% in Tuesday's trading session, plunging to around $47.80 from Monday's closing price of $64.61. The devastating selloff — which wiped out approximately $1.7 billion in market capitalization — came in reaction to the company's second-quarter fiscal 2026 earnings report, which was released after the bell on Monday. While the headline numbers showed record revenue and an adjusted EBITDA beat, a deeper look revealed slowing user growth, net income deterioration, and forward guidance that left analysts unconvinced about the company's near-term trajectory.

Q2 Earnings: A Beat That Wasn't Good Enough

Life360 reported second-quarter revenue of $159 million, up 38% year-over-year and modestly above the $156.7 million analyst consensus. Subscription revenue rose 31% to $115.6 million, driven by a 27% increase in Paying Circles to 3.2 million and a 5% increase in average revenue per Paying Circle. Advertising revenue was a standout, surging 315% to a record $22 million, reflecting the early contribution from the Nativo acquisition completed earlier this year. Adjusted EBITDA jumped 53% to $31.1 million, handily beating the $25.5 million consensus estimate.

Yet beneath the surface, several metrics rattled investor confidence. GAAP net income dropped 28% to just $5.1 million, or $0.06 per share — missing the $0.08 consensus. The net income margin compressed to 3% from 6% a year ago. Operating expenses climbed 43% to $127 million, outpacing the 38% revenue growth rate, as the company ramped up investments in R&D, sales and marketing, and the integration of its newly acquired advertising platform. For a stock trading at a premium growth multiple, the margin of error was razor-thin — and the report fell short of the perfection the market had priced in.

MAU Growth Deceleration: The Metric That Matters Most

For Life360, monthly active users represent the top-of-funnel engine that drives both subscription and advertising revenue. In Q2, global MAUs grew 16% year-over-year to 102.4 million — marking the first time the company crossed the 100-million-user milestone but also representing a second consecutive quarter of deceleration, down from 17% growth in Q1.

Management maintained its full-year MAU growth target of approximately 20%, but analysts on the earnings call pressed for concrete, quantifiable evidence that a second-half reacceleration is achievable. The response was largely qualitative: executives pointed to early back-to-school momentum, rising brand awareness in international markets, and upcoming pet-related product initiatives. Without hard data to back the optimism, investors interpreted the confidence gap as a signal that the growth trajectory may be softening more than management was willing to acknowledge.

Guidance Held Steady — And That Was the Problem

Life360 reaffirmed its full-year revenue guidance of $650 million to $685 million and adjusted EBITDA guidance of $130 million to $140 million. While the company raised its subscription revenue forecast by $5 million at the midpoint (to $475 million–$480 million), it simultaneously lowered hardware revenue guidance by the same amount, keeping the consolidated outlook unchanged. The revenue midpoint of roughly $667.5 million sits about 1% below the FactSet consensus of $671.8 million — a modest gap that, for a high-growth stock, carries outsized weight.

Adding to the unease, management guided for a Q3 adjusted EBITDA margin of approximately 18%, which disappointed analysts who noted the sequential improvement appeared sluggish outside of a one-time tariff benefit. The full-year margin target of roughly 20% now leans heavily on a strong fourth quarter, where the company must exceed the 22% margin it posted in Q4 2025. This back-end-loaded setup introduces execution risk at a moment when investor patience is already frayed.

Revenue Mix Shift and Margin Quality Concerns

The rapid growth in advertising revenue, while impressive at 315%, brings with it structurally lower margins than the core subscription business. Advertising gross margin came in at approximately 57%, compared with subscription gross margins in the high-80% range. As advertising grows as a share of total revenue — it accounted for 13.8% of quarterly sales, up from 4.6% a year ago — blended profitability metrics face natural downward pressure. Additionally, the advertising business is inherently more cyclical and sensitive to macroeconomic conditions, introducing variability that subscription-only models avoid. For a market already skeptical about the quality of Life360's earnings composition, this mix shift added another layer of concern.

Market Context and Trading Activity

The selloff in LIF was dramatic in both speed and magnitude. After closing Monday's regular session at $64.61, the stock collapsed roughly 24% in after-hours trading and continued to slide as Tuesday's regular session unfolded. Volume was overwhelmingly elevated relative to the daily average, reflecting a rush for the exits by momentum-oriented investors and algorithmic trading systems that dominate post-earnings price action in high-beta technology names.

The decline was idiosyncratic rather than sector-driven. Broader technology indices did not exhibit comparable weakness, confirming that the move was a direct reaction to company-specific fundamentals rather than a macro or sector-wide rotation. The stock, which carries a beta of approximately 2.35, has a history of violent post-earnings swings — it dropped 10.8% after Q1 results in May before recovering within roughly three weeks.

What Comes Next for LIF

The immediate question facing LIF is whether the post-earnings selloff represents a buying opportunity — as the post-Q1 dip proved to be — or the beginning of a more sustained re-rating. Much depends on third-quarter execution. The back-to-school season is historically Life360's strongest period for user acquisition, and the planned relaunch of Pet GPS with a bundled subscription model represents a potential catalyst for both MAU growth and Paying Circle expansion. The Apple Watch app, currently in beta, could broaden the user funnel to younger children and aging adults.

On the risk side, the advertising business faces seasonal headwinds, and the macroeconomic environment remains uncertain — CEO Lauren Antonoff acknowledged in post-earnings interviews that consumer health is a variable the company cannot fully control. The unchanged full-year guidance leaves little room for error, and any further deceleration in MAU growth would likely trigger another round of multiple compression. Analysts maintain a consensus "Moderate Buy" rating, but recent price target reductions from firms including UBS (lowered to $60 from $64) suggest that even bullish voices are recalibrating expectations.

Trending AI Robots

For investors seeking to navigate volatile market environments with data-driven precision, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to shifting market conditions. Tickeron provides hundreds of AI trading bots covering thousands of tickers across diverse strategies and timeframes, but only the strongest performers under current market dynamics are featured in this regularly updated section. Each bot varies by trading strategy, historical performance metrics, and the symbols it targets, allowing traders to identify approaches aligned with their objectives. Explore the Trending AI Robots page to discover which automated strategies are currently delivering standout results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LIF

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


LIF's Stochastic Oscillator is sitting in overbought zone for 7 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for LIF moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LIF broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on LIF as a result. In of 32 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LIF just turned positive on August 04, 2026. Looking at past instances where LIF's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LIF advanced for three days, in of 148 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 110 cases where LIF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LIF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.795) is normal, around the industry mean (28.441). P/E Ratio (37.057) is within average values for comparable stocks, (81.498). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.723). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (10.515) is also within normal values, averaging (69.431).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Adobe (NASDAQ:ADBE), Datadog (NASDAQ:DDOG), Intuit (NASDAQ:INTU), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 10.35B. The market cap for tickers in the group ranges from 291 to 237.4B. SAP holds the highest valuation in this group at 237.4B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 4%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 8%. YXT experienced the highest price growth at 117%, while NXTT experienced the biggest fall at -100%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 1%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was -54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
LIF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.